Published on in Vol 10 (2024)
Preprints (earlier versions) of this paper are
available at
https://preprints.jmir.org/preprint/53807, first published
.

Journals
- Lloyd P, Acharya G, Zhao H, Shah N, Anguzu G, Ambarsoomzadeh D, Clarke T, Ng X, Hu M, Chillarige Y, Forshee R, Anderson S. Safety monitoring of health outcomes following influenza vaccination during the 2023–2024 season among U.S. Medicare beneficiaries aged 65 years and older. Vaccine 2025;53:127069 View
- Pan Y, Han Y, Zhou C, Zhao L, Zheng J, Ye X, He Y, Chute C. Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study. Nature Communications 2025;16(1) View
- Asturias E, Chen L, Shaw A, Moser C, Maldonado Y, Zucker J, Chu H, Talbot H, Cineas S, Lyons K, Schechter R, Kamboj M, Wiley Z, Brewer N. Science for vaccine policy: Independent review of the September 2025 ACIP processes, deliberations and votes. Vaccine 2025;67:127876 View
- Scott J, Abers M, Marwah H, McCann N, Meyerowitz E, Richterman A, Fleming D, Holmes E, Moat L, Redepenning S, Smith E, Stoddart C, Sundaram M, Ulrich A, Alba C, Anderson C, Arpey M, Borre E, Ladines-Lim J, Mehr A, Rich K, Watts C, Basta N, Jarolimova J, Walensky R, Dugdale C. Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025–2026. New England Journal of Medicine 2025;393(22):2221 View
